Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer
Authors:
- A. AthanasiouAAA. Athanasiou
- N. ZirasNZN. Ziras
- J. AngelJAJ. Angel
- A. RaptiARA. Rapti
- S. LampakiSLS. Lampaki
- N. PolitisNPN. Politis
- C. KaranikasCKC. Karanikas
- C. KosmasCKC. Kosmas
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 68 (2) , 240-247
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patientsLung Cancer, 2009
- Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trialLung Cancer, 2008
- Phase 1 trial of lipoplatin and gemcitabine as a second‐line chemotherapy in patients with nonsmall cell lung carcinomaCancer, 2008
- Activity of lipoplatin in tumor and in normal cells in vitroAnti-Cancer Drugs, 2008
- Docetaxel as Second Line Therapy in Advanced Non-small Cell Lung Cancer—The Dose and Combination May Matter!Journal of Thoracic Oncology, 2008
- Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and GemcitabineOncology, 2007
- A Phase II Study of the Docetaxel- Ifosfamide-Carboplatin Combination in Advanced Non-Small-Cell Lung CancerOncology, 2005
- Cisplatin nephrotoxicitySeminars in Nephrology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Neurotoxic side-effects of cisplatinEuropean Journal of Cancer and Clinical Oncology, 1991